European Journal of Experimental Biology
ISSN: 2248-9215

Open access Opinion

The Association of Antibiotic Exposure with New Onset Inflammatory Bowel Disease

Xuezhang Zhou*

Department of Life Science, University of Ningxia, China

INTRODUCTION

Antibiotics have revolutionized modern medicine by providing effective treatment options for bacterial infections. Since the discovery of penicillin in 1928, antibiotics have saved countless lives and improved public health worldwide. However, the journey of antibiotics from laboratory breakthroughs to clinical use involves several crucial stages. This article aims to explore the different stages of antibiotics, from their discovery and development to their eventual utilization in clinical settings. The discovery stage marks the initial step in the development of antibiotics. Historically, the discovery of antibiotics often occurred by chance. The first antibiotic, penicillin, was discovered by Sir Alexander Fleming in 1928 when he noticed that a mold, Penicillium, inhibited bacterial growth. This chance observation laid the foundation for subsequent antibiotic discoveries. Today, the discovery of new antibiotics involves a combination of systematic screening and innovative research. Scientists employ various approaches, such as studying the chemical compounds produced by microorganisms or investigating the mechanisms by which certain bacteria inhibit the growth of others. Advances in genomics and high-throughput screening techniques have significantly accelerated the discovery process, leading to the identification of new antibiotic candidates. Once a potential antibiotic compound is identified, it enters the development stage. This phase involves extensive laboratory research and preclinical studies to assess the compound's efficacy, safety, and pharmacokinetic properties. Scientists conduct *in vitro* experiments and animal studies to evaluate the antibiotic's effectiveness against a wide range of bacterial strains. The development stage also encompasses chemical modification and optimization of the antibiotic compound to enhance its potency, stability, and bioavailability.

DESCRIPTION

Medicinal chemists collaborate with microbiologists to make structural modifications that improve the drug's activity against target bacteria while minimizing side effects. Furthermore, preclinical studies focus on determining the pharmacokinetics of the antibiotic, including its absorption, distribution, metabolism, and elimination within the body. These studies provide essential insights into dosing regimens and potential drug interactions. Clinical trials form a critical stage in the evaluation of antibiotics. These trials are conducted in three distinct phases to determine the drug's safety, efficacy, and optimal dosage regimens. Phase I trials involve a small number of healthy volunteers and aim to establish the drug's safety profile, dosage range, and potential side effects. The emphasis is on assessing the drug's pharmacokinetics, absorption, distribution, metabolism, and excretion in humans. Phase II trials expand the study population to include individuals with the targeted infection. These trials assess the antibiotic's efficacy in treating the infection while monitoring its safety and side effects in a larger patient cohort. Phase III trials involve a more extensive patient population and compare the effectiveness of the new antibiotic with existing treatments or placebos. These trials provide essential data on the drug's overall safety and efficacy, informing regulatory agencies and healthcare providers about its potential benefits. Upon successful completion of clinical trials, the antibiotic developer submits a New Drug Application (NDA) to the appropriate regulatory agency, such as the U.S. Food and Drug Administration (FDA).

CONCLUSION

The stages of antibiotics, from discovery to clinical use, involve a complex and rigorous process that ensures their safety and

Received:	01-March-2023	**Manuscript No:**	EJEBAU-23-16629
Editor assigned:	03-March-2023	**PreQC No:**	EJEBAU-23-16629 (PQ)
Reviewed:	17-March-2023	**QC No:**	EJEBAU-23-16629
Revised:	22-March-2023	**Manuscript No:**	EJEBAU-23-16629 (R)
Published:	29-March-2023	**DOI:**	10.36648/2248-9215.13.1.10

Corresponding author Xuezhang Zhou, Department of Life Science, University of Ningxia, China, E-mail: zhou_xuezhang@nxu.edu.cn

Citation Zhou X (2023) The Association of Antibiotic Exposure with New Onset Inflammatory Bowel Disease. Eur Exp Bio. 13:10.

efficacy. Scientists and healthcare professionals work together to identify potential antibiotic compounds, optimize their properties, conduct clinical trials, and gain regulatory approval. Furthermore, ongoing surveillance and monitoring contribute to our understanding of the long-term effects and challenges associated with antibiotic use. By comprehending the stages of antibiotics, we can appreciate the significant efforts behind these life-saving medications and work towards the responsible use and preservation of these invaluable resources.